Public Company News

Infosys: Revenue guidance for FY22 revised upwards to 19.5%-20.0%, powered by sequential growth of 7.0% in Q3

BENGALURU, India, Jan. 12, 2022 /PRNewswire/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, delivered strong Q3 performance with sequential growth of 7.0% in a seasonally weak quarter and year-on-year growth of 21.5% in constan...

2022-01-12 20:53 10350

South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, today...

2022-01-12 20:43 3051

CICC's Dr. Huang Haizhou Receives the 19th Sun Yefang Economic Science Award

BEIJING, Jan. 12, 2022 /PRNewswire/ -- Dr. Huang Haizhou, Managing Director, a member of the Management Committee and Head of the Equity Business Department of CICC, together withPatrick Bolton, Professor of Economics and Finance at Columbia University, have received the 19th Sun Yefang Prize for...

2022-01-12 20:32 4759

OMD'S GUY MARKS NAMED CEO OF OMNICOM MEDIA GROUP EMEA

NEW YORK, Jan. 12, 2022 /PRNewswire/ -- Omnicom Media Group, the media services division ofOmnicom Group Inc. (NYSE: OMC) has named Guy Marks CEO of Omnicom Media Group EMEA. In his new role, Marks, previously leader of OMD EMEA, will oversee strategy, operations and the development and adoption ...

2022-01-12 20:00 3041

Invitation to media and analyst briefing for Ericsson Q4 and full year 2021 report

STOCKHOLM, Jan. 12, 2022 /PRNewswire/ -- Ericsson's (NASDAQ: ERIC) financial report for the fourth quarter and full year of 2021 will be published at approximately7:00 AM CET on January 25, 2022. The company will issue a press release with the complete financial report attached, including tables...

2022-01-12 17:16 3041

Crunchfish announces 12th Gesture Interaction patent

STOCKHOLM, Jan. 12, 2022 /PRNewswire/ -- Crunchfish Gesture Interaction AB ("Crunchfish") has received an Intention to Grant from the European Patent Office (EPO) regarding gesture interaction with a physical or virtual display to type PIN codes or passwords in a unique way every time. The patent...

2022-01-12 15:54 2149

Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCC

SUZHOU, China, Jan. 12, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the TST001 US P...

2022-01-12 15:15 3760

ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease

* ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease * ABL301 uses ABL's Grabody-B platform technology to ef...

2022-01-12 07:59 4085

IBM Acquires Envizi to Help Organizations Accelerate Sustainability Initiatives and Achieve Environmental Goals

ARMONK, N.Y., Jan. 11, 2022 /PRNewswire/ -- IBM (NYSE: IBM) today announced it has acquired Envizi, a leading data and analytics software provider for environmental performance management. This acquisition builds on IBM's growing investments in AI-powered software, including IBM Maximo asset mana...

2022-01-11 21:00 5038

SOPHiA GENETICS Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study

BOSTON and LAUSANNE, Switzerland, Jan. 11, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today strong traction in the launch phase of their DEEP-Lung-IV clinical study (NCT0...

2022-01-11 20:27 2347

Semiconductor Manufacturing International Corporation Fourth Quarter 2021 Webcast Conference Call

SHANGHAI, Jan. 11, 2022 /PRNewswire/ -- SMIC's fourth quarter 2021 results will be released on the Hong Kong Stock Exchange website (https://www.hkex.com.hk ) and Shanghai Stock Exchange website ( http://www.sse.com.cn ) after the close of trading ...

2022-01-11 18:39 6670

Aim Strong Growth in Business Results and Actively Deliver Returns to Shareholders

HONG KONG, Jan. 11, 2022 /PRNewswire/ -- CNOOC Limited (the "Company", SEHK: 00883) today announces a summary of its business strategy and development plan for the year 2022. The Company's targeted net production for 2022 is 600 million to 610 million barrels of oil equivalent (BOE), of which,...

2022-01-11 16:50 5068

Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets

SHANGHAI and NEW YORK, Jan. 11, 2022 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare group inChina and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)...

2022-01-11 16:30 4312

Pixelworks Powers OnePlus 10 Pro Flagship to Deliver Superior Visual Experience

Showcases Always True-To-Life Color Appearance with Great Eye-Comfort Regardless ofAmbient Lighting Conditions SHANGHAI, Jan. 11, 2022 /PRNewswire/ -- Pixelworks, Inc. (NASDAQ: PXLW), a leading provider of innovative video and display processing solutions, and OnePlus, a premium global smartphon...

2022-01-11 16:00 3479

Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster

TIANJIN, China, Jan. 11, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced thatPreprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet, published a clinical study on the safety and immunogenicity of ...

2022-01-11 15:15 3196

TI advances driver assistance technology to more accurately monitor blind spots and efficiently navigate turns and corners to safely avoid collisions

HANOI, Vietnam, Jan. 11, 2021 /PRNewswire/ -- In an effort to move autonomous driving and vehicle safety forward, Texas Instruments (TI) (Nasdaq: TXN) today announced an expansion of its automotive offerings that can help automakers improve how advanced driver assistance systems (ADAS) sense ob...

2022-01-11 15:00 2675

LTI Partners with Securonix & Snowflake to Strengthen Cybersecurity Offerings

MUMBAI, India, Jan. 11, 2022 /PRNewswire/ -- Larsen & Toubro Infotech  (BSE: 540005) (NSE: LTI ), a global technology consulting and digital solutions company has partnered with Securonix, a leader in next-gen Security Informa...

2022-01-11 13:51 3773

XCMG Launches First Silk Road E-Commerce Station, XCMG-PNG, Offering One-Stop Equipment Purchases in South Pacific Regions

XUZHOU, China, Jan. 11, 2022 /PRNewswire/ -- XCMG Papua New Guinea (XCMG-PNG), the first Silk Road E-Commerce Station by XCMG (SZ:000425), is officially online to provide one-stop service experience for construction machinery customers and users in the South Pacific and surrounding regions withPa...

2022-01-11 10:57 4275

Pfizer Drives Cultural Change in Sustainable and Accessible Data with MicroStrategy

SINGAPORE, Jan. 11, 2022 /PRNewswire/ -- MicroStrategy , the US-based enterprise analytics platform, supportedPfizer, an American multinational pharmaceutical and biotechnology corporation, to usher in a future of sustainable data culture. With the help of solut...

2022-01-11 09:30 3187

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication

HANGZHOU, China and SHAOXING, China, Jan. 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC42 for chronic hepatitis B (CHB) indication. The Phase II clinical trial (ClinicalTrials.gov Identifier: NCT051...

2022-01-11 08:30 4092
1 ... 797798799800801802803 ... 901